Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 8, 2017

Debiopharm begins dosing in Phase Ib solid tumours trial

Switzerland-based Debiopharm International has started dosing patients in a Phase Ib clinical trial of Debio 1143 to treat advanced solid tumours.  

Switzerland-based Debiopharm International has started dosing patients in a Phase Ib clinical trial of Debio 1143 to treat advanced solid tumours.

Being conducted as part of the firm’s ongoing clinical collaboration with the Merck-Pfizer Alliance, the trial will involve combination of the investigational agent with avelumab.

Debio 1143 is a potent, orally available inhibitor of apoptosis proteins (IAP) with immunomodulatory properties. It has the ability to promote apoptosis of cancer cells by imitating the natural second mitochondrial-derived activator of caspases (SMAC).

The dual mechanism of action of Debio 1143 is expected to improve treatment outcomes in cancer patients administered with a combination of immunotherapy, chemotherapy and/or radiotherapy.

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody with the potential to leverage adaptive and innate immune systems.

“This is the first time this combination is being investigated in patients.”

The multi-centre, dose-finding, open-label Phase Ib trial will evaluate the safety and potential efficacy of the combination therapy in patients who did not receive previous immunotherapy.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

An adaptive dose-escalation part of the trial designed to find a recommended Phase II dose of Debio 1143 in combination with a standard avelumab dose will be followed by an expansion part, including 37 subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Debiopharm International Oncology medical director Sergio Szyldergemajn said: “We are very excited to conduct this Phase Ib study to evaluate the potential of combining our Debio 1143 molecule with avelumab.

“This is the first time this combination is being investigated in patients and we are looking forward to assessing the therapeutic potential of our compound in the immuno-oncology space.”

Merck and Pfizer formed a partnership to co-develop and co-commercialise avelumab in 2014, while Debiopharm signed the collaboration agreement with the Merck-Pfizer Alliance last year.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU